biotech / news / / Benzinga
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is the first and only subcutaneously administered therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) Compared to
FDA approved Rybrevant Faspro as the first subcutaneous therapy for EGFR-mutated NSCLC.
KEY POINTS
- Rybrevant Faspro reduces administration time to five minutes and lowers adverse reactions versus IV.
- SC Rybrevant showed longer duration of response, progression-free survival, and overall survival than IV.
- FDA expanded TRUFILL n-BCA approval for embolization of the MMA to treat subdural hematoma.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →